68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangioendothelioma

Derlin, Thorsten; Hueper, Katja; Soudah, B.

doi:10.1097/rlu.0000000000001814

Cited by 9 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epithelioid hemangioendothelioma (EHE) is a rare low-grade tumor originating from vascular endothelial or pre-endothelial cells with the potential to metastasize and recur [ 89 ]. Derlin et al [ 74 ] described a case where [ 68 Ga]Ga-DOTATATE and [ 18 F]FDG identified vertebral metastasis from EHE. [ 68 Ga]Ga-DOTATATE demonstrated a higher tumor to background ratio.…”

Section: Discussionmentioning

confidence: 99%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [18F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…68 Ga-DOTA-NOC, consisting of 68 Ga-DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid) complex conjugated to the somatostatin analog 1 (1-NaI3-octreotide, NOC) has been used for the detection of a broad range of tumor types and their metastases, as for example parotid basal cell adenoma, medulloblastoma, neuroblastoma and bronchial carcinoids [47][48][49][50]. Another complex using a different somatostatin analog (Tyr3-octreotate, TATE), 68 Ga-DOTA-TATE has also been used in several tumor-type detection and is part of ongoing clinical trials for metastatic castration-resistant prostate cancer diagnostics [51,52]. Edotreotide (TOC), with a special affinity for type 2 somatostatin receptors has also been used combined with 68 Ga-DOTA ( 68 Ga-DOTA-TOC) to diagnose cancerous lesions [53][54][55].…”

Section: Small Molecule Clinical Applications Of 68 Gamentioning

confidence: 99%

Molecular Imaging with 68Ga Radio-Nanomaterials: Shedding Light on Nanoparticles

et al. 2018

View full text Add to dashboard Cite

Abstract:The combination of radioisotopes and nanomaterials is creating a new library of tracers for molecular imaging, exploiting the sensitivity of nuclear imaging techniques and the size-dependent properties of nanomaterials. This new approach is expanding the range of applications, including the possibility of theranostics. Among the many different combinations, the use of 68 Ga as the radioisotope in the radio-nanomaterial is particularly convenient. The physicochemical properties of this isotope allow incorporating it into many materials with great chemical flexibility. Furthermore, its production from a benchtop generator eases the preparation of the tracer. Here, we review main results from the last years in which a nanomaterial has been radiolabeled with 68 Ga. In thus process, we pay attention to the use of nanomaterials for biomedical imaging in general and main properties of this radioisotope. We study the main methods to carry out such radiolabeling and the most important applications for molecular imaging.

show abstract

“…PET/CT studies with different agents have shown that 18 F-FDG PET/CT is useful in the diagnosis of EHE as well as in the detection of recurrence 7 . 68 Ga-DOTATATE PET/CT imaging showed intense activity uptake in EHE metastases 8 . 68 Ga-FAPI PET/CT has been shown to be superior to 18 F-FDG PET/CT in bone metastases of EHE 9 .…”

mentioning

confidence: 96%

68Ga-PSMA Versus 18F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma

Şenses,

Kaplan,

Kaya

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

A 32-year-old man with epithelioid hemangioendothelioma was imaged with 68Ga-PSMA PET/CT to evaluate the potential of 177Lu-PSMA radionuclide therapy after progression findings were observed on follow-up 18F-FDG PET/CT imaging. Liver lesions showed low FDG SUVmax. The lesion-to-background ratio (TBR) was calculated as 5.1/2.9 on 18F-FDG PET/CT imaging. However, 68Ga-PSMA PET/CT showed moderate PSMA SUVmax. TBR was calculated as 4.5/1.1. In conclusion, in this case report, we demonstrated that 68Ga-PSMA with moderate TBR in epithelioid hemangioendothelioma may be promising for 177Lu-PSMA radionuclide therapy.

show abstract

68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangioendothelioma

Cited by 9 publications

References 9 publications

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Molecular Imaging with 68Ga Radio-Nanomaterials: Shedding Light on Nanoparticles

68Ga-PSMA Versus 18F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma

Contact Info

Product

Resources

About